ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1198 • ACR Convergence 2023

    Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative

    Colin McLaughlin1, Grace Lo1, Jeffrey Driban2, Timothy McAlindon3, Andrea Kriska4, Bonnie Rockette-Wagner4, Marc Hochberg5, Michael Nevitt6, Kent Kwoh7 and Charles Eaton8, 1Baylor College of Medicine, Houston, TX, 2Tufts Medical Center, Westborough, MA, 3Tufts Medical Center, Arlington, MA, 4University of Pittsburgh, Pittsburgh, PA, 5University of Maryland School of Medicine, Baltimore, MD, 6University of California San Francisco, Orinda, CA, 7University of Arizona, Tucson, AZ, 8Brown University, Pawtucket, RI

    Background/Purpose: Bicycling is viewed as a non-weight bearing exercise and is often recommended as a preferred exercise for those with knee osteoarthritis (OA).However, there is…
  • Abstract Number: 1204 • ACR Convergence 2023

    Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies

    Maurice Flurie1, Monica Converse1, Christopher Parker2, Brian LaMoreaux3, Daniel Hernandez4, N. Lawrence Edwards5, Gary Ho1, Kristina Davidson6, E. Robert Wassman1, Christopher DeFelice1 and Maria Picone1, 1TREND Community, Philadelphia, PA, 2TREND Community, Austin, TX, 3Horizon Therapeutics, Deerfield, IL, 4Global Healthy Living Foundation, St. Johns, FL, 5University of Florida College of Medicine, Gainesville, FL, 6Horizon Therapeutics, Dublin, Ireland

    Background/Purpose: To comprehensively understand the impact of disease management strategies, it is essential to understand the patient perspective. Gout is a chronic inflammatory arthritis characterized…
  • Abstract Number: 1201 • ACR Convergence 2023

    Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, David Kane3 and Richard Conway4, 1St James's Hospital, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Ireland, 3Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…
  • Abstract Number: 1171 • ACR Convergence 2023

    Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies

    Caoilfhionn M. Connolly1, Jana Lovell2, Melody Chung3, Brittany Adler2, Jemima Albayda2, Eleni Tiniakou2, Christopher Mecoli1, Stefan Zimmerman2, Lisa Christopher-Stine2, Nisha Gilotra2 and Julie Paik2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Kaiser Permanante, Baltimore, MD

    Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its associated morbidity and mortality. As manifestations of myocarditis can be mild or subclinical…
  • Abstract Number: 1192 • ACR Convergence 2023

    Autoimmune Thyroid Disease Associates with Symptomatic Hand Osteoarthritis in Older Persons in the Third National Health and Nutrition Examination Survey

    Clement Tagoe1 and Wanyi Wang2, 1Albert Einstein College of Medicine, Bronx, NY, 2Elite Research, LLC, Irving, TX

    Background/Purpose: Osteoarthritis (OA) of the hand is associated with the presence of bony deformities in the proximal interphalangeal joints, distal interphalangeal joints, and first carpometacarpal…
  • Abstract Number: 1195 • ACR Convergence 2023

    Relationship of Depth-Specific Subchondral Bone Mineral Density to MRI Cartilage Worsening: The Multicenter Osteoarthritis Study

    Jean Liew1, JD Johnston2, Gabriela Rabasa1, Beth Lewis3, John Lynch4, James Torner5 and Tuhina Neogi6, 1Boston University, Boston, MA, 2University of Saskatchewan, Saskatoon, SK, Canada, 3University of Alabama at Birimingham, Birmingham, AL, 4University of California San Francisco, San Francisco, CA, 5University of Iowa, Iowa City, IA, 6Boston University School of Medicine, Boston, MA

    Background/Purpose: While OA has been considered a disease of cartilage, early subchondral bone changes may precede cartilage abnormalities. Although higher systemic BMD has a known…
  • Abstract Number: 1207 • ACR Convergence 2023

    Cardiovascular Mortality of Acute Myocardial Infraction and Acute Heart Failure Hospitalization in Rheumatic Diseases Patients Evaluation from the 2016-2020 National Inpatient Sample (NIS) Database

    Zi Ying Li1, Siyi Huang2, senay Gokcebel3 and Anthony Reginato4, 1Roger Williams Medical Center, Providence, RI, 2UCSF Fresno, Fresno, CA, 3School of Public Health | Brown University, Providence, RI, 4The Warren Alpert Medical School of Brown University, Providence, RI

    Background/Purpose: Rheumatic diseases such as rheumatoid arthritis (RA) and Systemic lupus erythematosus (SLE) were known for increased prevalence and risk of death from cardiovascular disease…
  • Abstract Number: 1208 • ACR Convergence 2023

    Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study

    Francesca Cardwell1, Alexandra Kobza2, Susan Elliott1, paul Gibson2, Nancy Soliman2, leslie skeith2, Ann Clarke3 and Megan R.W. Barber2, 1University of Waterloo, Waterloo, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

    Background/Purpose: Substantial morbidity and mortality affect those with aPLs and APS, yet the patient experience remains poorly understood. This research investigated patient experiences of aPL/APS…
  • Abstract Number: 1104 • ACR Convergence 2023

    Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

    Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY

    Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without…
  • Abstract Number: 1194 • ACR Convergence 2023

    Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain

    Kent Kwoh1, Frank Roemer2, Erin Ashbeck3 and Ali Guermazi4, 1University of Arizona, Tucson, AZ, 2Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany, 3University of Arizona Arthritis Center, Tucson, AZ, 4Boston University, Boston, MA

    Background/Purpose: Subchondral bone marrow lesions (BMLs) have been associated with incident and progressive pain and reported to fluctuate along with concurrent fluctuations in symptoms. While…
  • Abstract Number: 1164 • ACR Convergence 2023

    Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study

    Carina Soto-Fajardo1, Sinthia Solorzano Flores1, Abish Angeles-Acuña1, Fabian Carranza Enriquez1, Rosa-Elena Escobar-Cedillo2, Saul Renan-Leon2, Karina Arias Callejas3, Alejandra Enriquez-Luna2, Graciliano Ramon-Diaz2 and Carlos Pineda2, 1Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, 2Instituto Nacional de Rehabilitacion, Mexico City, Mexico, 3Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico

    Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…
  • Abstract Number: 1199 • ACR Convergence 2023

    Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan

    Hsiang-Yen Lee1, Ching-Kuei Chang1, Tzu-Min Lin1, Tzu-Tung Ku2, Jin-Hua Chen2, Yu-Hsiu Chen3, Shu-Chuan Chen4 and Chi-Ching Chang2, 1Taipei Medical University Hospital, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Tri-Service General Hospital, Taipei, Taiwan, 4Idaho State University, Idaho State Pocatello, ID

    Background/Purpose: Cellular senescence is involved in osteoarthritis (OA) development. Dipeptidyl Peptidase-4 (DPP4) is associated with senescence in OA chondrocytes. It is uncertain whether DPP4 inhibitor…
  • Abstract Number: 1119 • ACR Convergence 2023

    Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice

    Silvia Sirotti1, Joao Madruga-Dias2, Antonella Adinolfi3, Garifallia Sakellariou4, Davide Rozza5, Greta Carrara5, Gianpiero Landolfi5, Carlo Alberto Scire5, Annamaria Iagnocco6 and Georgios Filippou1, 1IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, 2Centro Hospitalar do Médio Tejo, NOVA Medical School, Lisbon, Portugal, 3Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, 4Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, 5Società Italiana di Reumatologia, Epidemiology Research Unit, Milan, Italy, 6University of Turin, Roma, Italy

    Background/Purpose: The RADIAL study is aimed to evaluate the performance of a composite approach, based on clinical, laboratory and ultrasound (US) data in the differential…
  • Abstract Number: 1093 • ACR Convergence 2023

    Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases

    Liam Huppke1, Paul Wratil2, Marie Bischof2, Stefan Wolfrum1, Fabian Ullrich1, Delila Singh1, Julia Lichtnekert1, Lea Grümme1, Christina Gebhardt1, Klaus Krüger3, Franziska Wiesent4, Alla Skapenko1, Oliver Keppler5 and Hendrik Schulze-Koops6, 1Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 2Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU Munich, Munich, Germany, 3Praxiszentrum St. Bonifatius, Munich, Germany, 4Endokrinologikum München, Munich, Germany, 5Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU München, Munich, Germany, 6Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany

    Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…
  • Abstract Number: 1109 • ACR Convergence 2023

    Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

    Blanka Stiburkova1, Katerina Pavelcova2, Jana Masinova1, Marketa Pavlikova3 and Karel Pavelka4, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Praha 2, Czech Republic, 3Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, 4Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic

    Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
  • « Previous Page
  • 1
  • …
  • 374
  • 375
  • 376
  • 377
  • 378
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology